1
|
Danesin N, Bonaldi L, Martines A, Nalio S, Bertorelle R, Compagno S, Marcato R, Manni S, Scarmozzino F, Pizzi M, Tos APD, Cellini A, Scapinello G, Visentin A, Trentin L, Piazza F. Impact of the presence and number of chromosomal abnormalities on the clinical outcome in Waldenström Macroglobulinemia: a monocentric experience. Ann Hematol 2024:10.1007/s00277-024-05770-4. [PMID: 38687347 DOI: 10.1007/s00277-024-05770-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2024] [Accepted: 04/19/2024] [Indexed: 05/02/2024]
Abstract
The prognostic and predictive role of specific gene mutations in Waldenström Macroglobulinemia (WM) is well-ascertained whereas the clinical impact of chromosome aberrations is far less known. Recent work has provided initial evidence for an adverse prognostic impact of some aberrations, such as del(6q), while other studies suggest a possible relationship between some clinical features (e.g. advanced age and/or inflammatory status) and specific cytogenetic abnormalities. To add to the still limited knowledge on WM cytogenetics and its clinical implications, we herein report our experience in a cohort of WM patients across 23 years. Based on our retrospective study, we found that abnormal karyotype was more represented in older patients and maintained a statistically significant independence from other molecular, clinical, and biological features related to WM. The presence and number of cytogenetic aberrations correlated with inferior overall and progression-free survival outcomes regardless of the type of single chromosome aberration. Our data suggests that the role of the altered karyotype deserves to be further clarified especially in elderly WM patients, in whom cytogenetic abnormalities and disease biology appear to be characterized by a higher degree of complexity.
Collapse
Affiliation(s)
- Nicolò Danesin
- Hematology Unit, Department of Medicine, University of Padova, Via Giustiniani 2, 35128, Padua, Italy
| | - Laura Bonaldi
- Immunology and Molecular Oncology Diagnostics, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy
| | - Annalisa Martines
- Immunology and Molecular Oncology Diagnostics, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy
| | - Silvia Nalio
- Immunology and Molecular Oncology Diagnostics, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy
| | - Roberta Bertorelle
- Immunology and Molecular Oncology Diagnostics, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy
| | - Sofia Compagno
- Immunology and Molecular Oncology Diagnostics, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy
| | - Raffaella Marcato
- Immunology and Molecular Oncology Diagnostics, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy
| | - Sabrina Manni
- Hematology Unit, Department of Medicine, University of Padova, Via Giustiniani 2, 35128, Padua, Italy
- Veneto Institute of Molecular Medicine, Fondazione Per La Ricerca Biomedica Avanzata, Padua, Italy
| | - Federico Scarmozzino
- Surgical Pathology and Cytopathology Unit, Department of Medicine, University of Padova, Padua, Italy
| | - Marco Pizzi
- Surgical Pathology and Cytopathology Unit, Department of Medicine, University of Padova, Padua, Italy
| | - Angelo Paolo Dei Tos
- Surgical Pathology and Cytopathology Unit, Department of Medicine, University of Padova, Padua, Italy
| | - Alessandro Cellini
- Hematology Unit, Department of Medicine, University of Padova, Via Giustiniani 2, 35128, Padua, Italy
| | - Greta Scapinello
- Hematology Unit, Department of Medicine, University of Padova, Via Giustiniani 2, 35128, Padua, Italy
| | - Andrea Visentin
- Hematology Unit, Department of Medicine, University of Padova, Via Giustiniani 2, 35128, Padua, Italy
| | - Livio Trentin
- Hematology Unit, Department of Medicine, University of Padova, Via Giustiniani 2, 35128, Padua, Italy
| | - Francesco Piazza
- Hematology Unit, Department of Medicine, University of Padova, Via Giustiniani 2, 35128, Padua, Italy.
- Veneto Institute of Molecular Medicine, Fondazione Per La Ricerca Biomedica Avanzata, Padua, Italy.
| |
Collapse
|
2
|
Martines A, Grassi A, Visentin A, Facco M, Nalio S, Sacchetto V, Pagnin E, Cellini A, Bertorelle R, Trentin L, Bonaldi L. The added value of karyotype in predicting the need for therapy in chronic lymphocytic leukemia with 13q deletion. Hematol Oncol 2023; 41:951-953. [PMID: 37401030 DOI: 10.1002/hon.3201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/05/2023]
Affiliation(s)
- Annalisa Martines
- Immunology and Molecular Oncology Diagnostics, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy
| | - Angela Grassi
- Immunology and Molecular Oncology Diagnostics, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy
| | - Andrea Visentin
- Hematology and Clinical Immunology Unit, Department of Medicine DIMED, University of Padua, Padua, Italy
| | - Monica Facco
- Hematology and Clinical Immunology Unit, Department of Medicine DIMED, University of Padua, Padua, Italy
| | - Silvia Nalio
- Immunology and Molecular Oncology Diagnostics, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy
| | - Valeria Sacchetto
- Immunology and Molecular Oncology Diagnostics, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy
| | - Elisa Pagnin
- Hematology and Clinical Immunology Unit, Department of Medicine DIMED, University of Padua, Padua, Italy
| | - Alessandro Cellini
- Hematology and Clinical Immunology Unit, Department of Medicine DIMED, University of Padua, Padua, Italy
| | - Roberta Bertorelle
- Immunology and Molecular Oncology Diagnostics, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy
| | - Livio Trentin
- Hematology and Clinical Immunology Unit, Department of Medicine DIMED, University of Padua, Padua, Italy
| | - Laura Bonaldi
- Immunology and Molecular Oncology Diagnostics, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy
| |
Collapse
|
3
|
Barilà G, Bonaldi L, Grassi A, Martines A, Liço A, Macrì N, Nalio S, Pavan L, Berno T, Branca A, Calabretto G, Carrino M, Teramo A, Manni S, Piazza F, Semenzato G, Zambello R. Identification of the true hyperdiploid multiple myeloma subset by combining conventional karyotyping and FISH analysis. Blood Cancer J 2020; 10:18. [PMID: 32066724 PMCID: PMC7026173 DOI: 10.1038/s41408-020-0285-6] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2019] [Revised: 11/18/2019] [Accepted: 11/20/2019] [Indexed: 01/22/2023] Open
Affiliation(s)
- Gregorio Barilà
- Department of Medicine (DIMED), Hematology and Clinical Immunology section, Padua University School of Medicine, Padua, Italy
| | - Laura Bonaldi
- Immunology and Molecular Oncology Unit, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy
| | - Angela Grassi
- Immunology and Molecular Oncology Unit, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy
| | - Annalisa Martines
- Immunology and Molecular Oncology Unit, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy
| | - Albana Liço
- Department of Medicine (DIMED), Hematology and Clinical Immunology section, Padua University School of Medicine, Padua, Italy
| | - Nadia Macrì
- Immunology and Molecular Oncology Unit, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy
| | - Silvia Nalio
- Immunology and Molecular Oncology Unit, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy
| | - Laura Pavan
- Department of Medicine (DIMED), Hematology and Clinical Immunology section, Padua University School of Medicine, Padua, Italy
| | - Tamara Berno
- Department of Medicine (DIMED), Hematology and Clinical Immunology section, Padua University School of Medicine, Padua, Italy
| | - Antonio Branca
- Department of Medicine (DIMED), Hematology and Clinical Immunology section, Padua University School of Medicine, Padua, Italy
| | - Giulia Calabretto
- Department of Medicine (DIMED), Hematology and Clinical Immunology section, Padua University School of Medicine, Padua, Italy
| | - Marilena Carrino
- Department of Medicine (DIMED), Hematology and Clinical Immunology section, Padua University School of Medicine, Padua, Italy
| | - Antonella Teramo
- Department of Medicine (DIMED), Hematology and Clinical Immunology section, Padua University School of Medicine, Padua, Italy
| | - Sabrina Manni
- Department of Medicine (DIMED), Hematology and Clinical Immunology section, Padua University School of Medicine, Padua, Italy
| | - Francesco Piazza
- Department of Medicine (DIMED), Hematology and Clinical Immunology section, Padua University School of Medicine, Padua, Italy
| | - Gianpietro Semenzato
- Department of Medicine (DIMED), Hematology and Clinical Immunology section, Padua University School of Medicine, Padua, Italy
| | - Renato Zambello
- Department of Medicine (DIMED), Hematology and Clinical Immunology section, Padua University School of Medicine, Padua, Italy.
| |
Collapse
|
4
|
Indraccolo S, Lombardi G, Fassan M, Pasqualini L, Giunco S, Marcato R, Gasparini A, Candiotto C, Nalio S, Fiduccia P, Fanelli GN, Pambuku A, Della Puppa A, D'Avella D, Bonaldi L, Gardiman MP, Bertorelle R, De Rossi A, Zagonel V. Genetic, Epigenetic, and Immunologic Profiling of MMR-Deficient Relapsed Glioblastoma. Clin Cancer Res 2018; 25:1828-1837. [PMID: 30514778 DOI: 10.1158/1078-0432.ccr-18-1892] [Citation(s) in RCA: 67] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2018] [Revised: 09/25/2018] [Accepted: 11/28/2018] [Indexed: 11/16/2022]
Abstract
PURPOSE In-depth characterization of recurrent glioblastoma (rGBM) might contribute to a better understanding of the mechanisms behind tumor progression and enable rGBM treatment with targeted drugs.Experimental Design: In this study, GBM samples were collected at diagnosis and recurrence from adult patients treated with Stupp protocol. Expression of mismatch repair (MMR) proteins was evaluated by IHC, followed by whole exome sequencing (WES) of tumor samples showing loss of MSH6 reactivity. Established genetic, epigenetic, and immunologic markers were assessed by standard methods and correlated with loss of MMR proteins and patient survival. RESULTS Expression of MMR proteins was partially or completely lost in 25.9% rGBM samples. Specifically, 12 samples showed partial or total MSH6 expression reduction. Conversely, 96.4% of GBM samples at diagnosis expressed MMR markers. WES disclosed lack of variants in MMR genes in primary samples, whereas two MSH6-negative rGBM samples shared a c.3438+1G>A* splicing MSH6 variant with a potential loss of function effect. MSH6-negative rGBM specimens had high tumor mutational burden (TMB), but no microsatellite instability. In contrast, GBM samples with partial loss of MMR proteins disclosed low TMB. MMR-deficient rGBM showed significant telomere shortening and MGMT methylation and are characterized by highly heterogeneous MHC class I expression. CONCLUSIONS Multilevel profiling of MMR-deficient rGBM uncovered hypermutated genotype uncoupled from enriched expression of immune-related markers. Assessment of MHC class I expression and TMB should be included in protocols aiming to identify rGBM patients potentially eligible for treatment with drugs targeting immune-checkpoint inhibitors.
Collapse
Affiliation(s)
- Stefano Indraccolo
- Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV -IRCCS, Padova, Italy.
| | - Giuseppe Lombardi
- Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV -IRCCS, Padova, Italy
| | - Matteo Fassan
- Department of Medicine (DIMED), Surgical Pathology Unit, University of Padova, Padova, Italy
| | - Lorenza Pasqualini
- Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV -IRCCS, Padova, Italy
| | - Silvia Giunco
- Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV -IRCCS, Padova, Italy
| | - Raffaella Marcato
- Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV -IRCCS, Padova, Italy
| | - Alessandra Gasparini
- Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV -IRCCS, Padova, Italy
| | - Cinzia Candiotto
- Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV -IRCCS, Padova, Italy
| | - Silvia Nalio
- Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV -IRCCS, Padova, Italy
| | - Pasquale Fiduccia
- Clinical Trials and Biostatistics Unit, Veneto Institute of Oncology IOV -IRCCS, Padova, Italy
| | - Giuseppe Nicolò Fanelli
- Department of Medicine (DIMED), Surgical Pathology Unit, University of Padova, Padova, Italy
| | - Ardi Pambuku
- Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV -IRCCS, Padova, Italy
| | | | - Domenico D'Avella
- Neurosurgery, Department of Neurosciences DNS, University Hospital of Padova, Padova, Italy
| | - Laura Bonaldi
- Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV -IRCCS, Padova, Italy
| | - Marina Paola Gardiman
- Surgical Pathology and Cytopathology Unit, University Hospital of Padova, Padova, Italy
| | - Roberta Bertorelle
- Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV -IRCCS, Padova, Italy
| | - Anita De Rossi
- Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV -IRCCS, Padova, Italy.,Department of Surgery, Oncology and Gastroenterology (DISCOG), University of Padova, Padova, Italy
| | - Vittorina Zagonel
- Department of Oncology, Oncology 1, Veneto Institute of Oncology IOV -IRCCS, Padova, Italy
| |
Collapse
|